Skip to main content

Table 6 Health technology assessment information deemed to be important by stakeholders by country (scale responses: 1 = strongly disagree; 7 = strongly agree)

From: Similarities and differences between stakeholders’ opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey

  Netherlands Hungary Germany Spain United Kingdom Total Kruskal–Wallis test
Statements n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) P value
Prevalence of smoking 28 5.89 (1.34) 16 6.38 (1.41) 17 5.82 (1.55) 18 5.78 (1.96) 14 5.64 (2.41) 93 5.90 (1.69) 0.38
Costs of smoking 28 6.29 (0.85) 16 7.00 (0.00) 17 6.53 (0.62) 18 6.28 (1.41) 14 6.71 (1.07) 93 6.52 (0.94) 0.002
Quality of life 28 5.79 (1.32) 16 6.13 (1.26) 17 5.41 (1.87) 18 6.06 (1.39) 14 5.86 (1.10) 93 5.84 (1.40) 0.63
Mortality due to smoking 28 6.11 (1.26) 16 6.75 (1.00) 17 5.88 (1.93) 18 6.33 (1.03) 14 6.64 (1.34) 93 6.30 (1.35) 0.010
Effectiveness of smoking cessation interventions (such as quit and relapse rates) 28 6.39 (1.20) 16 6.50 (1.27) 17 6.18 (1.67) 18 6.39 (1.42) 14 6.71 (1.07) 93 6.42 (1.31) 0.35
Cost-effectiveness data comparing the cost of smoking cessation interventions with its health and wider benefits 28 6.43 (0.88) 16 6.69 (0.48) 17 6.18 (1.02) 18 6.78 (0.43) 14 6.86 (0.36) 93 6.56 (0.74) 0.093
Budget impact reflecting financialoutcomes specifically at organisational level 28 6.07 (1.25) 16 6.69 (0.60) 17 6.00 (1.37) 18 6.67 (0.49) 14 6.00 (1.47) 93 6.27 (1.13) 0.17
  1. SD, Standard deviation